Table 2.
Target | Name | Content | Vendor | Current status |
MiR34 | MRX34 | Liposome-formulated miR-34 mimic | Mirna Therapeutics | Phase I |
VEGF/KSP | ALN-VSP | RNAi targeting VEGF/KSP | Alnylam Pharmaceuticals | Phase I |
PLK1 | TMK-PLK1 | RNAi targeting PLK1 | Tekmira Pharmaceuticals | Phase I/II |
MiR21 | Anti-miR21 | Antisense against miR21 | Regulus Therapeutics | Preclinical |
MiR221 | Anti-miR221 | Antisense against miR221 | Regulus Therapeutics | Preclinical |
MiR7 | MiR7 mimic | MiR7 mimic | MiReven | Preclinical |
VEGF: Vascular endothelial growth factor; KSP: Kidney-specific cadherin; PLK1: Polo-like kinase 1.